摘要
目的评价恩度(重组人血管内皮抑素,endostar,YH-16)联合GP(吉西他滨+顺铂)治疗老年性晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法 72例老年性晚期NSCLC患者被随机分为两组,试验组(40例)应用YH-16联合GP方案,对照组(32例)予以常规GP方案化疗。两组患者均至少完成2个周期。结果试验组有效率(RR)为42.5%,临床获益率(CBR)为80.0%;对照组有效率(RR)28.13%,临床获益率(CBR)为56.2%。两组毒副反应相似,患者的主要毒副反应有恶心、呕吐、白细胞减少等。结论恩度联合GP方案治疗老年性晚期NSCLC是一种有效、安全的方案。
Objective To evaluate the efficacy and security of endostar injection combined with GP regimen for the treat- ment of elderly advanced non- small cell lung cancer （NSCLC）. Methods Seventy- two elderly patients with advanced non - small cell lung cancer were randomly divided into two groups. 40 patients served as trial group were treated with the combina- tion of YH- 16 with GP regimen, while 32 patients as control group only received GP regimen. At least after two cycles, the ef- ficacy and toxicity were evaluated in all patients. Results The efficiency rates of trial group and control group were 42.5 % and 28.13%, respectively. The clinical benefit rates in trial group and control group were 80.0% and 56.2%, respectively. The side- effects were similar in the two groups, including nausea, vomiting and neutropenia. Conclusions YH - 16 combined with GP is an effective and safe therapy for elderly advanced NSCLC.
出处
《实用预防医学》
CAS
2012年第8期1230-1232,共3页
Practical Preventive Medicine
关键词
非小细胞肺癌
老年性
恩度
GP
Non - small cell lung cancer
Elderly
Endostar
GP regimen
